Deliverables

Deliverablesalbert2023-05-08T08:40:48+00:00

September 21, 2023

WP3 - Clinical validation studies (Prospective studies)

D3.5 Mid-term recruitment report for Study 2 (PROMISE case-control validation study)
September 21, 2023

WP3 - Clinical validation studies (Prospective studies)

D3.4 Final study approvals package for Study 1 and 2

21.09.2023

WP2 - Preparation of future RSV product assessment

D2.1 Open-access online tool to continuously measure RSV awareness
06.07.2023

WP2 – Preparation for future RSV product assessment

D2.6 Generic protocols for effectiveness studies of preventive products against RSV
06.07.2023

WP2 – Preparation for future RSV product assessment

D2.5 Report on consultations with Health Authorities on data elements needed for Phase IV studies
06.06.2023

WP3 - Clinical validation studies

D3.3 Full institutional review board (IRB) approval
06.06.2023

WP3 - Clinical validation studies

D3.2 Database development for patient recruitment, characterisation and sample allocation
06.06.2023

WP2 – Preparation for future RSV product assessment

D2.3 Report on various effectiveness endpoints for clinical outcomes in RSV studies

Acknowledgement

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement 101034339. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

The Innovative Medicines Initiative is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). It is working to improve health by speeding up the development of the next generation of medicines, particularly in areas where there is an unmet medical or social need. It works by facilitating collaboration between the key players involved in health research, including universities, research centres, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. IMI is the world’s biggest public-private partnership (PPP) in the life sciences.

© 2023 | IMI-Promise

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept all”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent. Cookie Settings Accept all Reject

Tracking Cookies

Collect information about user navigation through the site in order to know the origin of the visits and other similar data at a statistical level.

Tracking Cookies

Third Party Embeds

Google Maps

Twitter
Google Maps

Cookies policy

Cookies policy

Privacy policy

Privacy policy